Skip to main content

Clinical trial SELINDA

A Phase IB study of oral selinexor in adult patients with relapsed/refractory B-cell lymphoma receiving R-DHAOx or R-GDP

Organ Lymphome non-hodgkinien
Trial status Trial open for recruitment
Trial type
Interventionnal with IMP
Phase Trial phase 2
Academic trial Non
Sponsor Lysarc
EudraCT Identifier 2015-005612-15
Inclusion criteria Eligible to receive R-GDP - with at least one but no more than two lines therapies - no previous treatment with Selinexor
Last update